



## Company Announcement

### Clinuvel appoints Head of Corporate Development

**Melbourne, Australia August 21<sup>st</sup> 2007**

Clinuvel Pharmaceuticals Limited (ASX:CUV) is proud to announce the appointment of Colin Mackie (BA Dip Ed, Grad. Dip Applied Finance, Senior Fellow FINSIA) as Head of Corporate Development.

#### Evolution of Clinuvel

Based in Melbourne, Colin will be a key member of the Corporate Development Team, assisting to position Clinuvel as a pharmaceutical company and a leader in the prevention of UV related skin disorders.

Colin brings 15 years of experience in corporate investment management to Clinuvel. In his recent position at Tolhurst, Colin was the research analyst for the healthcare sector.

We are delighted to see Colin join Clinuvel at this exciting stage in the company's development.

He provides Clinuvel with a wealth of experience across a range of roles at Tolhurst, Australian Unity Funds Management, Invesco/County Investment Management and National Mutual.

CEO Philippe Wolgen, said this morning: "As Clinuvel evolves to a next stage in its business cycle, it will require senior professionals with a varied background. I am delighted to welcome Colin to our team. His, skill set and experience will aid to build Clinuvel to the global company I envisage."

#### About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited (ASX:**CUV**, XETRA/DAX:**UR9**, ADR:**CUVLY**) is an Australian biopharmaceutical company developing its photo-protective drug CUV1647 as a preventative treatment for a range of UV-related skin disorders as well as in cancer related treatments.

The five indications are:

Indication	Description	Clinical Trial Status
Polymorphic Light Eruption (PLE / PMLE)	Sun poisoning	Phase III trials began May 2007
Erythropoietic Protoporphyrria (EPP)	Absolute sun intolerance	Phase III trials began June 2007
Squamous Cell Carcinoma (SCC) and Actinic Keratosis (AK) in organ transplant patients	Non-melanoma skin cancers / precursor to skin cancers	Phase II trials planned to begin 2007
Solar Urticaria (SU)	Acute anaphylactic reaction to sun	Phase II trials planned to begin 2007

Phototoxicity associated with Photodynamic Therapy (PDT)	Photo-sensitivity associated with cancer treatment	Phase II trials planned to begin 2007
--	--	---------------------------------------

Phase I and II human clinical trials using CUV1647 have demonstrated that the drug is well tolerated and no significant safety concerns have been identified to date.

Following successful conclusion of the development program, Clinuvel will work closely with global regulators to facilitate marketing approval of CUV1647.

**-END-**

**For more information contact:**

**Colin Mackie  
Head of Corporate Development  
Clinuvel Pharmaceuticals Limited  
Tel: +61 3 9660 4900  
investorrelations@clinuvel.com**

Clinuvel is an Australian biopharmaceutical company focussed on developing its leading drug candidate, CUV1647, for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for CUV1647 can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for CUV1647 is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

**Level 11 / 330 Collins Street  
Melbourne, Victoria 3000  
Australia**

**T +61 3 9660 4900  
F +61 3 9660 4999**

**[clinuvel.com](http://clinuvel.com)**